Full text is available at the source.
Abstract
Current evidence indicates the potential for very low levels of low-density lipoprotein cholesterol (LDL-C) in dyslipidaemia management.
- More-intensive LDL-C lowering may lead to different clinical outcomes compared to less-intensive approaches.
- The study focuses on the use of statins and recommended non-statin medications for secondary prevention.
- Current treatments could significantly affect the management of dyslipidaemia.
Simplified